Compare GRRR & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRRR | ARMP |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United Kingdom | United States |
| Employees | 200 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.5M | 383.7M |
| IPO Year | N/A | 1996 |
| Metric | GRRR | ARMP |
|---|---|---|
| Price | $13.35 | $9.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 780.3K | 68.3K |
| Earning Date | 06-17-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.35 | N/A |
| Revenue Next Year | $85.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.04 | $1.17 |
| 52 Week High | $27.90 | $14.98 |
| Indicator | GRRR | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 40.60 |
| Support Level | $12.13 | $5.14 |
| Resistance Level | $15.83 | $12.11 |
| Average True Range (ATR) | 0.86 | 1.47 |
| MACD | -0.14 | -0.28 |
| Stochastic Oscillator | 33.39 | 8.21 |
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments. Its expertise lies in revolutionizing urban operations, enhancing security, and optimizing digital transformation. It delivers pioneering products that integrate AI, deep learning, and edge computing to advance intelligent video surveillance, facial recognition, license plate recognition, post-event analytics, cybersecurity, and network intelligence.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.